A sepsis management answer may differ between the US and the UK — different guideline bodies, different antibiotic formularies, different escalation pathways, different clinical governance frameworks. A prescribing answer certainly differs — different licensed indications, different formulations, different monitoring requirements, different regulatory authorities. Medical AI that does not account for these differences is not just less useful — it is potentially unsafe.
What Doximity Ask Does Well
Doximity Ask (formerly DoxGPT) is the clinical AI assistant within Doximity's Clinical AI Suite, used by 300,000+ unique clinicians in the most recent quarter. It sits inside a platform where 85% of US physicians are already registered — alongside Scribe (ambient documentation), Dialer (HIPAA-compliant calling), and professional networking.
The August 2025 Pathway Medical acquisition added 3,200+ drug monographs and structured clinical evidence. PeerCheck provides physician-led review with 10,000+ reviewers. The platform offers full PDF access to top medical journals, chart-note templates, patient education material, translation, and literacy-level adjustment.
For US physicians, Doximity Ask is a strong product in a strong ecosystem. The distribution advantage — sitting inside the platform US doctors already use daily — creates the same structural adoption benefit that Accurx Scribe has in UK primary care.
Why UK Clinicians Need UK Clinical AI
UK clinical practice operates within a different evidence and governance ecosystem. NICE and CKS provide the guideline framework — not ACC/AHA, ADA, or IDSA. SmPC/eMC provides regulated product and prescribing information approved by the MHRA — not FDA-approved drug labels or Lexicomp. MHRA Drug Safety Updates provide UK-specific safety alerts — not FDA MedWatch. UK referral pathways vary by ICB, Trust, and locality — not US insurance-driven specialist referral. UK professional exams (MRCP, MRCGP AKT, PLAB, UKMLA, GPhC CRA) test UK guideline knowledge — not USMLE content.
A clinical AI tool trained on US medical content — however well-validated by US physicians — may provide answers that do not reflect UK prescribing practice, UK-licensed indications, UK monitoring requirements, or UK referral thresholds. The answer may be medically correct in a US context and clinically inappropriate for a UK patient.
Where iatroX Differs
iatroX is built for clinicians and healthcare professionals working in UK-style clinical contexts. Its knowledge architecture uses curated UK sources — NICE, CKS, SmPC/eMC, MHRA drug safety updates, SIGN — rather than unrestricted internet retrieval. Medicines information is powered via eMC/SmPC, providing UK-regulated product data rather than US drug labels.
The platform combines clinical AI with UK-specific features that Doximity Ask does not offer: 80+ clinical calculators with UK guideline references, 15+ adaptive exam Q-banks covering UK and international exams, and CPD logging aligned with GMC/GPhC revalidation requirements.
Trust: Physician Validation vs Source-Grounded UK Fidelity
Doximity's PeerCheck adds physician review — US specialists validating US-oriented clinical AI outputs. iatroX's trust architecture adds source-grounded UK fidelity — algorithmic controls designed to keep outputs aligned with retrieved UK guideline and medicines information, with fail-safe behaviour when evidence is insufficient and feedback mechanisms for clinician quality reporting.
Both address clinical AI trust. Each addresses it for its own clinical jurisdiction. Neither translates perfectly to the other's market.
Conclusion
Doximity Ask is a major US signal — validating that clinical AI is becoming an essential physician workflow tool. iatroX is a UK-focused response to the same deeper problem: clinicians need fast, trusted, verifiable clinical answers grounded in the sources their healthcare system actually uses.